Celonic and Glycotope announced the completion of Celonic’s acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany.
The acquisition is expected to accelerate topline growth, driven by expanded GMP manufacturing assets and by an immediate investment in capacity for late-stage and commercial supply.
"With on-boarding of almost two decades of invaluable experience in optimization of perfusion continuous manufacturing processes, Celonic is well positioned to offer our customers the flexibility and the advantages of perfusion and fed-batch manufacturing – from pilot to commercial scale,” Dr. Konstantin Matentzoglu, Celonic's Chief Executive Officer, said. “Also, adding Glycotope’s highly complementary GEX human cell line platform to Celonic’s innovative CHOvolution integrated development platform gives our pharmaceutical and biotech customers the unique opportunity to select a tailored expression system, suitable for their bio-therapeutics development needs.”